SPR2015 / SciBrunch Therapeutics - LARVOL DELTA

SPR2015, a highly potent and selective KRAS G12D (on) inhibitor, exhibits favorable pharmacokinetic behavior and significant anti-tumor efficacy against colorectal cancer as monotherapy in preclinical models (AACR 2026) - "On the safety part, SPR2015 demonstrated favorable in vitro safety profiles and was well-tolerated in a 28-day rodent repeat dosing tox studies. SPR2015 is currently under IND-enabling and is expected to advance to human Phase 1 study by the end of 2026."

Monotherapy • PK/PD data • Preclinical • Colorectal Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • DUSP6 • KRAS